Biotech | January 04, 2022
USFDA grants ILiAD Biotechnologies Fast Track Designation for pertussis vaccine
BPZE1 is the most advanced next-generation pertussis vaccine currently in clinical development
BPZE1 is the most advanced next-generation pertussis vaccine currently in clinical development
Healthy growth in domestic and emerging markets is expected to support revenue growth in the next few quarters
Molflu is expected to be available from early next week in pharmacies throughout the country with a particular focus on states with a high caseload of Covid-19.
Partnering to build biosynthesis processes and a pharmaceutical production platform
Emergency Use Authorisation application request to be submitted following one month required by FDA EUA guidance
A toll-free helpline to be set up to help doctors and patients
ASC10 is an oral direct-acting antiviral drug candidate targeting RNA dependent RNA polymerase (RdRp) to treat SARS-CoV-2 infection
First emergency use authorization in the United States for a Covid-19 vaccine booster in adolescents 12 through 15 years of age
The contract award from the U.S. Department of Defense (DoD), on behalf of the U.S. Department of Health and Human Services, is part of an effort to ensure secure local supply and production capacity for critical products for pandemic preparedness
Rapid antigen testing provides results in just 15 minutes and the information can help reduce the risk of Covid-19 exposure
Subscribe To Our Newsletter & Stay Updated
